# Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)

> **NCT01265199** · PHASE1 · TERMINATED · sponsor: **Ascenta Therapeutics** · enrollment: 29 (actual)

## Conditions studied

- Acute Myelogenous Leukemia (AML)

## Interventions

- **DRUG:** AT-406 in combination with daunorubicin and cytarabine

## Key facts

- **NCT ID:** NCT01265199
- **Lead sponsor:** Ascenta Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-02
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Study was terminated before a MTD was determined for administrative reasons
- **Last updated:** 2013-01-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265199, "Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Properties of Oral AT-406 in Combination With Daunorubicin and Cytarabine in Patients With Poor-risk Acute Myelogenous Leukemia (AML)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01265199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*